Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07242105 · ClinicalTrials.gov registry record · NA
Optimizing Brain Excitability in Depression
A NA study of Major Depressive Disorder, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 145
- Enrollment target
- 2
- Study locations
NCT07242105: Recruiting NA study of Major Depressive Disorder, sponsored by Stanford University.
NCT07242105 is a NA study of Major Depressive Disorder that is actively recruiting participants, run by Stanford University. The registered enrollment target is 145 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07242105, a NA study of Major Depressive Disorder, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 145 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).
Primary Outcome
Changes in Early Local TMS-Evoked Potentials (EL-TEP) following 6 hours of either active or sham spTMS between optimized and non-optimized stimulation conditions in the anterior dlPFC.
Conditions Studied
Interventions
- DEVICE Active Single-Pulse TMS
- DEVICE Sham Single-Pulse TMS
- DEVICE TARGET-optimized TMS
- DEVICE Non-optimized (Open-Loop) TMS
- OTHER EEG Recording
Study Locations (2)
California
- University of Iowa - Iowa City
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2029-11-30 |
| Phase | NA |
What NCT07242105 shows while recruiting
NCT07242105 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 5 interventions - of which Active Single-Pulse TMS is the first listed.
NCT07242105 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07242105 about?
NCT07242105 is a clinical study titled "Optimizing Brain Excitability in Depression". The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).
What is the current status of trial NCT07242105?
This trial is currently recruiting. It is a NA study. The enrollment target is 145 participants. The study started on 2025-10-23. Estimated completion is 2029-11-30.
What conditions does trial NCT07242105 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT07242105?
The interventions under investigation include: Active Single-Pulse TMS (DEVICE), Sham Single-Pulse TMS (DEVICE), TARGET-optimized TMS (DEVICE), Non-optimized (Open-Loop) TMS (DEVICE), EEG Recording (OTHER).
Who is sponsoring clinical trial NCT07242105?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07242105 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07242105's enrollment target sits among peer trials
145 105th of 282 higher than 178 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI